Form 4: Esperion Therapeutics Director Reports Stock Transaction
Insider Transaction (Form 4)
John Craig Thompson, a Director of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.
Summary
- Disposition to the issuer: disposed of 79,873 Common Stock on July 13, 2026 (Direct).
- Disposition to the issuer: disposed of 40,000 Stock Option (right to buy) on July 13, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
John Craig Thompson — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-13 | Disposition to the issuer | Common Stock | 79,873 | — | — | 0 |
| 2026-07-13 | Disposition to the issuer | Stock Option (right to buy) | 40,000 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-13 | Disposition to the issuer (79,873 shares) |
| 2026-07-13 | Disposition to the issuer (40,000 shares) |
Keywords
insider transaction, Form 4, ESPR, Esperion Therapeutics, Inc., neutral, John Craig Thompson
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.